Caliway Biopharmaceuticals C, TW0006919004

MarketScreener targets Caliway Biopharmaceuticals C stock at TWD 240.00

Published on 10/14/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CBL-514 reached 69.60 percent response on October 2, 2026. Caliway Biopharmaceuticals C stock receives a TWD 240 target in September 2026.

Clinical data and analyst valuation

CBL-514 produced a 69.60 percent response after eight weeks in phase 2 on October 2, 2026.
Visceral fat fell 12.00 percent against a 5.68 percent placebo increase in the reported study.
MarketScreener listed a TWD 240.00 average target on September 22, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

MarketScreener listed a TWD 240.00 average target for Caliway Biopharmaceuticals C stock on September 22, 2026, while the company's CBL-514 program advanced toward phase 3 after positive phase 2 data. The target is set against clinical evidence showing a 69.60 percent response after eight weeks, making trial execution the central valuation issue.

Three dated development steps

On September 21, 2026, Canada authorized an amendment to a phase 3 CBL-514 study, according to MarketScreener. On October 2, 2026, Caliway and the University of Alabama at Birmingham presented phase 2 findings for CBL-514 at the European Association for the Study of Diabetes meeting, as DongA Science reported.

On October 13, 2026, pharmaphorum said Caliway was preparing two placebo-controlled phase 3 trials. The sequence gives the stock a clear clinical catalyst, but it also shifts attention from proof of concept to recruitment, safety and the durability of the treatment effect.

What does phase 3 change?

The phase 2 results were differentiated by the mechanism as well as the headline response. According to pharmaphorum, 69.60 percent of treated participants reduced subcutaneous fat by at least 150 milliliters after eight weeks, compared with 0.00 percent for placebo.

Visceral fat also moved in opposite directions: the treated group recorded a 12.00 percent reduction, while placebo increased 5.68 percent. DongA Science reported that 41 adults took part, with 23 receiving CBL-514 and 18 receiving placebo. Those figures are promising, but the phase 3 program must establish whether the result holds in a larger population.

Next reported date

Caliway's next results date is November 11, 2026, according to Investing.com. The same earnings page lists second-quarter 2026 revenue of TWD 3.57 million and a net loss of TWD 222.52 million, figures that underline the company's development-stage profile.

Valuation meets clinical execution

The TWD 240.00 average target cited by MarketScreener on September 22, 2026 places substantial weight on the clinical path. For investors, the next measurable checkpoints are the two phase 3 trials, the November 11, 2026 reporting date and confirmation that the 69.60 percent response can translate into a broader result.